61 related articles for article (PubMed ID: 36906857)
41. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
Dixit V; Hariparsad N; Li F; Desai P; Thummel KE; Unadkat JD
Drug Metab Dispos; 2007 Oct; 35(10):1853-9. PubMed ID: 17639026
[TBL] [Abstract][Full Text] [Related]
42. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
43. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes.
Madan A; Graham RA; Carroll KM; Mudra DR; Burton LA; Krueger LA; Downey AD; Czerwinski M; Forster J; Ribadeneira MD; Gan LS; LeCluyse EL; Zech K; Robertson P; Koch P; Antonian L; Wagner G; Yu L; Parkinson A
Drug Metab Dispos; 2003 Apr; 31(4):421-31. PubMed ID: 12642468
[TBL] [Abstract][Full Text] [Related]
44. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture.
Badolo L; Jensen B; Säll C; Norinder U; Kallunki P; Montanari D
Xenobiotica; 2015 Feb; 45(2):177-87. PubMed ID: 25183402
[TBL] [Abstract][Full Text] [Related]
46. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
47. Cannabidiol's impact on drug-metabolization.
Stöllberger C; Finsterer J
Eur J Intern Med; 2023 Dec; 118():6-13. PubMed ID: 37541924
[TBL] [Abstract][Full Text] [Related]
48. 3D Spheroid Primary Human Hepatocytes for Prediction of Cytochrome P450 and Drug Transporter Induction.
Järvinen E; Hammer HS; Pötz O; Ingelman-Sundberg M; Stage TB
Clin Pharmacol Ther; 2023 Jun; 113(6):1284-1294. PubMed ID: 36906857
[TBL] [Abstract][Full Text] [Related]
49. Drug metabolism and drug transport of the 100 most prescribed oral drugs.
Iversen DB; Andersen NE; Dalgård Dunvald AC; Pottegård A; Stage TB
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):311-324. PubMed ID: 35972991
[TBL] [Abstract][Full Text] [Related]
50. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
[TBL] [Abstract][Full Text] [Related]
51. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions.
Martin P; Czerwiński M; Limaye PB; Ogilvie BW; Smith S; Boyd B
Pharmacol Res Perspect; 2022 Jun; 10(3):e00959. PubMed ID: 35599347
[TBL] [Abstract][Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]